Recent News

• 02.05.2026 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
• 11.26.2025 - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
• 11.18.2025 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
• 10.27.2025 - CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
• 10.20.2025 - CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
• 10.16.2025 - First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

Recent Filings

• 01.16.2026 - EFFECT Notice of Effectiveness
• 01.09.2026 - F-3 Registration statement by foreign private issuers
• 12.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.28.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.26.2025 - EX-99.1 EX-99.1
• 11.26.2025 - EX-99.1 EX-99.1
• 11.07.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 10.27.2025 - EX-99.1 EX-99.1